Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Eduardo Díaz-RubioM Homerin

Abstract

Oxaliplatin is a new cytotoxic agent from the diaminocyclohexane family with proven antitumor activity against colon cancer cell lines. Activity in patients with colorectal carcinoma previously treated with 5-fluorouracil has been studied in three single-agent phase II trials, showing a reproducible response rate of 10%. Here we report a phase II trial with oxaliplatin as a first-line chemotherapy for metastatic colorectal cancer. Twenty-five patients were entered in the study. All of them had metastatic disease without previous chemotherapy, and at least one lesion had to be measurable by computed tomography (CT). Therapy consisted of a two-hour infusion of oxaliplatin at a dose of 130 mg/m2 every 21 days. The overall response rate determined by investigators was 20% (95% CI, 6.8%-40.7%). Eight patients (32%) had stable disease. The median time to disease progression in responders was six months (range four to nine). The median progression-free survival was four months and median overall survival 14.5 months (95% CI, 10-20 months). The main toxic effects were peripheral neuropathy (92%) and laryngopharyngeal dysesthesia (75%). No severe grade 3-4 neurotoxicities (NCI-CTC) were found. Gastrointestinal and hematological toxiciti...Continue Reading

Citations

Mar 8, 2020·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Yoshiko MatsumotoSuguru Hasegawa
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S GiacchettiF Lévi
May 31, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian Chau, David Cunningham
Sep 27, 2003·Alimentary Pharmacology & Therapeutics·S GillR M Goldberg
Dec 12, 2003·Diseases of the Colon and Rectum·Li-Jen KuoChung-Ming Chen
Jun 24, 2004·Clinical Journal of Oncology Nursing·Joan SorichHoward Hochster
Oct 10, 2006·Future Oncology·Danish MazharWolfgang Heller
Oct 1, 2005·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Yoon Mi ShinKi Hyeong Lee
Jun 1, 2004·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Ji Young ParkKyung Sam Cho
Aug 13, 2011·Cell Death & Disease·R CoriatF Batteux
Dec 14, 2011·Expert Opinion on Pharmacotherapy·Alexander Stein, Dirk Arnold
Feb 16, 2012·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Nicole O Vietor, Benjamin J George
Apr 23, 2014·Journal of Evaluation in Clinical Practice·Ragnar WesterlingJohan P Mackenbach
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E WassermanE Cvitkovic
Jul 23, 1999·Current Opinion in Oncology·M E Royce, R Pazdur
Jan 5, 2001·Expert Opinion on Investigational Drugs·R Pazdur, M E Royce
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A de GramontA Bonetti
Aug 22, 2001·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·I GrivicichG Schwartsmann
Feb 4, 2005·The New England Journal of Medicine·Jeffrey A Meyerhardt, Robert J Mayer
Dec 6, 2005·Cancer Chemotherapy and Pharmacology·Hui K GanMatthew Links
May 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephanie R LandNorman Wolmark
Apr 13, 2007·Expert Opinion on Drug Metabolism & Toxicology·George P Kim, Charles Erlichman
Jul 28, 2007·Japanese Journal of Clinical Oncology·Narikazu BokuYusuke Tanigawara
Jun 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sheri L SpuntClinton F Stewart
Apr 9, 2009·American Journal of Therapeutics·Panagiotis HerasDimitrios Mitsibounas
Dec 1, 2006·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Duk-Joo LeeMyung-Ju Ahn
Feb 12, 2011·Expert Review of Gastroenterology & Hepatology·Colin R Lindsay, Jim Cassidy
Feb 16, 2018·Current Colorectal Cancer Reports·Lara HathoutSalma K Jabbour

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.